A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab.
advanced melanoma
biomarkers
immunotherapy
multivariate analysis
pembrolizumab
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Jan 2021
06 Jan 2021
Historique:
received:
29
11
2020
revised:
28
12
2020
accepted:
01
01
2021
entrez:
9
1
2021
pubmed:
10
1
2021
medline:
10
1
2021
Statut:
epublish
Résumé
Pembrolizumab improves the survival of patients with advanced melanoma. A comprehensive analysis of baseline variables that predict the benefit of pembrolizumab monotherapy has not been conducted. Survival data of patients with advanced melanoma who were treated with pembrolizumab in a single university hospital were collected. A multivariate Cox regression analysis was performed to correlate baseline clinical, laboratory, and radiologic characteristics and NanoString IO360 gene expression profiling (GEP) with survival. 183 patients were included (stage IV 85.2%, WHO performance status ≥1 31.1%; pembrolizumab first-line 25.7%), of whom 112 underwent baseline Multiple baseline variables correlate with survival on pembrolizumab. TMTV is a more comprehensive baseline biomarker than CRP, LDH, or ALC in predicting the futility of pembrolizumab.
Sections du résumé
BACKGROUND
BACKGROUND
Pembrolizumab improves the survival of patients with advanced melanoma. A comprehensive analysis of baseline variables that predict the benefit of pembrolizumab monotherapy has not been conducted.
METHODS
METHODS
Survival data of patients with advanced melanoma who were treated with pembrolizumab in a single university hospital were collected. A multivariate Cox regression analysis was performed to correlate baseline clinical, laboratory, and radiologic characteristics and NanoString IO360 gene expression profiling (GEP) with survival.
RESULTS
RESULTS
183 patients were included (stage IV 85.2%, WHO performance status ≥1 31.1%; pembrolizumab first-line 25.7%), of whom 112 underwent baseline
CONCLUSION
CONCLUSIONS
Multiple baseline variables correlate with survival on pembrolizumab. TMTV is a more comprehensive baseline biomarker than CRP, LDH, or ALC in predicting the futility of pembrolizumab.
Identifiants
pubmed: 33418936
pii: cancers13020168
doi: 10.3390/cancers13020168
pmc: PMC7825041
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Support Care Cancer. 2020 Jul;28(7):3267-3278
pubmed: 31745697
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
J Transl Med. 2019 Sep 5;17(1):303
pubmed: 31488153
Cell Res. 2017 Aug;27(8):1034-1045
pubmed: 28685773
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Ann Oncol. 2018 Oct 1;29(10):2115-2120
pubmed: 30137228
Science. 2016 May 6;352(6286):658-60
pubmed: 27151852
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2298-2310
pubmed: 31346755
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
Clin Cancer Res. 2016 Nov 15;22(22):5487-5496
pubmed: 27185375
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
J Clin Oncol. 2016 Dec;34(34):4102-4109
pubmed: 27863197
Ann Oncol. 2017 May 1;28(5):1130-1136
pubmed: 28327969
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021886
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Br J Cancer. 2016 Feb 2;114(3):256-61
pubmed: 26794281
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Lancet Oncol. 2016 Jul;17(7):976-983
pubmed: 27267608
Eur J Radiol. 2019 Dec;121:108688
pubmed: 31704599
Ann Oncol. 2019 Jul 1;30(7):1154-1161
pubmed: 30923820
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581
J Clin Oncol. 2020 Nov 20;38(33):3937-3946
pubmed: 32997575